Shawn E Yost
Overview
Explore the profile of Shawn E Yost including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alakus H, Yost S, Woo B, French R, Lin G, Jepsen K, et al.
J Transl Med
. 2015 Apr;
13:122.
PMID: 25889843
Background: Malignant mesothelioma (MM) arises from mesothelial cells that line the pleural, peritoneal and pericardial surfaces. The majority of MMs are pleural and have been associated with asbestos exposure. Previously,...
2.
Harismendy O, Schwab R, Alakus H, Yost S, Matsui H, Hasteh F, et al.
Breast Cancer Res
. 2013 Dec;
15(6):R115.
PMID: 24326041
Introduction: The increasing number of targeted therapies, together with a deeper understanding of cancer genetics and drug response, have prompted major healthcare centers to implement personalized treatment approaches relying on...
3.
He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, et al.
Cell
. 2013 Oct;
155(2):384-96.
PMID: 24120137
Hepatocellular carcinoma (HCC) is a slowly developing malignancy postulated to evolve from premalignant lesions in chronically damaged livers. However, it was never established that premalignant lesions actually contain tumor progenitors...
4.
Yost S, Alakus H, Matsui H, Schwab R, Jepsen K, Frazer K, et al.
Bioinformatics
. 2013 May;
29(15):1908-9.
PMID: 23712659
Summary: We present Mutascope, a sequencing analysis pipeline specifically developed for the identification of somatic variants present at low-allelic fraction from high-throughput sequencing of amplicons from matched tumor-normal specimen. Using...
5.
Yost S, Pastorino S, Rozenzhak S, Smith E, Chao Y, Jiang P, et al.
PLoS One
. 2013 Feb;
8(2):e56185.
PMID: 23441165
Recent advances in the ability to efficiently characterize tumor genomes is enabling targeted drug development, which requires rigorous biomarker-based patient selection to increase effectiveness. Consequently, representative DNA biomarkers become equally...
6.
Yost S, Smith E, Schwab R, Bao L, Jung H, Wang X, et al.
Nucleic Acids Res
. 2012 Apr;
40(14):e107.
PMID: 22492626
The utilization of archived, formalin-fixed paraffin-embedded (FFPE) tumor samples for massive parallel sequencing has been challenging due to DNA damage and contamination with normal stroma. Here, we perform whole genome...